Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease

AimsA strategy based on therapeutic drug monitoring and population pharmacokinetic (popPK) models would likely increase the rate of clinical remission (CR) after infliximab (IFX) induction in patients with Crohn’s disease (CD). This study aimed to evaluate the relationship between early IFX levels a...

Cijeli opis

Bibliografski detalji

Glavni autori:	Kouzhu Zhu, Xiaoliang Ding, Ling Xue, Linsheng Liu, Yan Wang, Yun Li, Qinhua Xi, Xueqin Pang, Weichang Chen, Liyan Miao
Format:	Artigo
Jezik:	Inglês
Izdano:	Frontiers Media S.A. 2024-08-01
Serija:	Frontiers in Pharmacology
Teme:	infliximab antibodies to infliximab Crohn’s disease clinical remission population pharmacokinetic model
Online pristup:	https://www.frontiersin.org/articles/10.3389/fphar.2024.1430120/full
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!